Across TCGA pan-cancer cohorts, LINC02503 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC02503’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where LINC02503 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02503 is over-expressed in tumor.
STAD are the cancer types where LINC02503 tumor–normal differential expression is most reproducible.